

**Steadview Capital Mauritius Ltd.**

---

4th Floor, Tower A, 1 CyberCity, Ebene, Mauritius

3 May 2018

To,  
The Listing Department  
Bombay Stock Exchange Ltd.  
PhirozeJeejeebhoy Towers,  
Dalal Street,  
Mumbai 400 001, India  
Fax No: +91-22-2272 1072

**Re: Purchase of equity shares and filings under the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011**

Dear Sirs,

With reference to the captioned matter, please find attached herewith the following:

1. Disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

We request you to kindly take the same on record.

Thanking you.

Yours truly,



Director,  
Steadview Capital Mauritius Limited

**CC:**

National Stock Exchange of India Ltd.  
Exchange Plaza,  
Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400 051, India  
Fax No.: +91-22-2659 8237 or 38

Neuland Laboratories Limited  
Sanali Info Park, 'A' Block, Ground Floor,  
8-2-120/113, Road No. 2, Banjara Hills,  
Hyderabad, 500034, Telangana, India  
Tel: +91 40 3021 1600  
Fax: +91 40 3021 1602  
Email: [neuland@neulandlabs.com](mailto:neuland@neulandlabs.com)

---

## Steadview Capital Mauritius Ltd.

*4th Floor, Tower A, 1 CyberCity, Ebene, Mauritius*

### **Format for Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

#### **Part –A- Details of the Acquisition**

Name of the Target Company (TC)	Neuland Laboratories Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Steadview Capital Mauritius Limited (Acquirer) LTR Focus Fund (PAC) ABG Capital (PAC)		
Whether the acquirer belongs to Promoter/Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	NSE,BSE		
Details of the acquisition as follows	<b>Number</b>	<b>% w.r.t. total share/voting capital wherever applicable(*)</b>	<b>% w.r.t. total diluted share/voting capital of the TC (**)</b>
<b>Before the acquisition under consideration, holding of acquirer along with PACs of:</b>			
a) Shares carrying voting rights			
b) Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/ others)	0	0%	0%
c) Voting rights (VR) otherwise than by equity shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	0	0%	0%
<b>e) Total (a+b+c)</b>	0	0%	0%
<b>Details of acquisition</b>			
a) Shares carrying voting rights acquired			
b) VRs acquired otherwise than by equity shares	635,817	5.70%	5.70%
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) sold.			

## Steadview Capital Mauritius Ltd.

*4th Floor, Tower A, 1 CyberCity, Ebene, Mauritius*

d) Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/ others)	519,899	4.66%	4.66%
<b>e) Total (a+b+c+-d)</b>	<b>1,155,716</b>	<b>10.36%</b>	<b>10.36%</b>
<b>After the acquisition, holding of acquirer along with PACs of:</b>	<b>Acquirer:</b>		
a) Shares carrying voting rights			
b) Shares in the nature of encumbrance (pledge/lien/ non-disposal undertaking/ others) Shares pledged with the acquirer.	635,817	5.70%	5.70%
c) VRs otherwise than by equity shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	<b>PACs:</b>		
	519,899	4.66%	4.66%
<b>e) Total (a+b+c)</b>	<b>1,155,716</b>	<b>10.36%</b>	<b>10.36%</b>
Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer, etc.)	Merger pursuant to scheme of amalgamation between Neuland Health Sciences Private Limited, Neuland Pharma Research Private Limited and Neuland Laboratories Limited		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares etc.	NA		
Date of acquisition of/ date of receipt of intimation of allotment of shares/ VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	1 May, 2018		
Equity share capital / total voting capital of the TC before the said acquisition	8,884,254 shares		
Equity share capital/ total voting capital of the TC after the said acquisition	11,154,889 shares		
Total diluted share/voting capital of the TC after the said acquisition	11,154,889 shares		

## Steadview Capital Mauritius Ltd.

4th Floor, Tower A, 1 CyberCity, Ebene, Mauritius

---

*Kave Mulla*

**Signature of the Acquirer / Authorised Signatory**

**Place: London**

**Date: 3 May 2018**

**Note:**

(\*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(\*\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(\*\*\*) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

---